纳米金-表阿霉素复合体的体外抗肿瘤作用

 摘 要：【目的】 观察纳米金-表阿霉素复合体(epirubicin-nanogold compounds, EPI- AuNP)能否抑制人脐静脉内皮细胞(human umbilical vein endothelial cells, HUVECs)、人肝癌细胞(HepG2)的增殖。【方法】 采用化学合成法制备EPI-AuNP，通过紫外-可见吸收光谱、荧光淬灭实验、动态光散射及Zeta电位变化对其进行鉴定。体外实验分为AuNP处理组、EPI处理组、EPI- AuNP处理组和空白对照组。将HUVECs、HepG2细胞分别接种于96孔板，培养24h后各组分别加入AuNP溶液、EPI溶液、EPI-AuNP溶液和无血清培养液200?l，继续培养24h后：MTT比色法检测HUVECs、HepG2细胞生存率；紫外-可见分光光度法检测各细胞内EPI的积聚量。【结果】 紫外-可见吸收光谱显示：AuNP的最大吸收峰在520nm处，而EPI-AuNP在525nm处。EPI (100mg/L)荧光强度为195.2±7.5；EPI-AuNP为16.4±5.0，P=0.000。AuNP的平均粒径及Zeta电位分别为：(14.34?0.75) nm、(-21.19?0.64)mV；EPI-AuNP为：(18.54?1.84)nm、(-15.34?0.72)mV，P<0.01。体外实验：MTT比色法结果显示EPI处理组HUVECs、HepG2细胞的生存率分别为(29.25? 1.59)%、(71.10?4.16)%；EPI-AuNP处理组：(21.29?1.51)%、(43.82?2.21)%，P=0.000。【结论】 成功合成EPI-AuNP复合体，体外实验证实其对HUVECs、HepG2细胞均具有增殖抑制作用。

In Vitro Antitumor Effects of Epirubicin-nanogold Compounds

【Objective】 To observe the in vitro antitumor effects of epirubicin-nanogold compounds(EPI-AuNP).【Methods】 EPI-AuNP was prepared by chemosynthesis and investigated using UV-Vis spectrophotometer,fluorescence studies,dynamic light scattering,and zeta potential.Human umbilical vein endothelial cells(HUVEC) and HepG2 cells were divided into 4 groups: AuNP treatment group,EPI treatment group,EPI-AuNP treatment group and control group.After seeded in 96-well plate and cultured for 24 h separately,HUVEC and HepG2 cells were treated with 200 uL of AuNP,EPI,EPI-AuNP,and serum-free medium,respectively.Inhibition effect of each group on the HUVEC and HepG2 cells was assessed using MTT colorimetric method.UV-Vis spectrophotometer was applied to detect the cells epirubicin accumulation of different groups.【Results】 A red shift in the SPR band maxima in the EPI-AuNP spectrum(λmax～525 nm) as compared with the spectrum of AuNP alone(λmax～520 nm);The fluorescence intensity of EPI(100 mg /L) was(195.2 ± 7.5) and EPI-AuNP was(16.4 ± 5.0),P=0.000.The hydrodynamic diameter of AuNP was(14.34 ± 0.75) nm while EPI-AuNP was(18.54 ± 1.84) nm.Meanwhile,the zeta potential of AuNP was(-21.19 ± 0.64) mV while EPI-AuNP was(-15.34 ± 0.72) mV,P<0.01.The HUVEC survival rate of EPI-AuNP treatment group (21.29 ± 1.51)%] was lower than the EPI group (29.25 ± 1.59)%].The HepG2 cells survival rate of EPI-AuNP treatment group (43.82 ± 2.21)%] was lower than the EPI group (71.10 ± 4.16)%],P<0.01.【Conclusions】 EPI-AuNP has been synthesized and indicated enhanced drug potency in vitro by MTT assay.